What is Ginkgo Bioworks Holdings's share price today?
Ginkgo Bioworks Holdings (DNA) share price today is $11.65 as of November 5, 2026 at 2:29 AM IST. The stock touched a day high of $11.75 and a day low of $10.84.What exchange does Ginkgo Bioworks Holdings stock trade on, and under what ticker symbol?
Ginkgo Bioworks Holdings stock trades on NYSE under the ticker symbol DNA.What is Ginkgo Bioworks Holdings's market capitalization?
Ginkgo Bioworks Holdings's market capitalization is $663.3M as of November 5, 2026 at 2:29 AM IST.What is Ginkgo Bioworks Holdings's price-to-earnings (P/E) ratio?
Ginkgo Bioworks Holdings's price-to-earnings (P/E) ratio is N/A as of November 4, 2026.What is Ginkgo Bioworks Holdings's price-to-book (P/B) ratio?
Ginkgo Bioworks Holdings's price-to-book (P/B) ratio is 1.79 as of November 4, 2026.Can Indian investors buy Ginkgo Bioworks Holdings shares?
Yes, You can buy Ginkgo Bioworks Holdings shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.How can I invest in Ginkgo Bioworks Holdings shares from India?
Indian investors can buy Ginkgo Bioworks Holdings shares in three steps: 1. Search Ginkgo Bioworks Holdings on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.How does USD-INR currency movement affect returns from Ginkgo Bioworks Holdings shares for Indian investors?
Since Ginkgo Bioworks Holdings trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.What is the minimum amount required to invest in Ginkgo Bioworks Holdings shares via Tickertape?
Indian investors can start investing in Ginkgo Bioworks Holdings (DNA) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.8577 shares at the current price of $11.65.
$
₹
$11.658.34% (+0.89)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max
Key Metrics
Key Metrics
PE TTM
PE TTM
Close price divided by the earnings per share for the trailing twelve months
—
PB
PB
Close price divided by the book value per share at the end of the most recent quarter
1.79
EPS TTM
EPS TTM
Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)
$-5.06
PEG Ratio
PEG Ratio
Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years
—
Profit Margin
Profit Margin
Net profit divided by the total revenue for the most recent financial year
-219.61%
Dividend Yield
Dividend Yield
Annual dividend per share for the trailing twelve months divided by the close price
—
Based on 3 analysts reports
Buy0 analyst
Hold1 analyst
Sell2 analysts
Price Upside
-25.65%
Earnings Growth
+48.14%
Rev. Growth
-50.01%
Company Profile
Company Profile
ABBV
P/E Ratio
50.67
50.67
1Y Return
32.47%
32.47%
Buy Reco %
79.31
79.31
AMGN
P/E Ratio
28.90
28.90
1Y Return
56.57%
56.57%
Buy Reco %
35.29
35.29
P/E Ratio
—
—
1Y Return
36.15%
36.15%
Buy Reco %
78.57
78.57
P/E Ratio
32.21
32.21
1Y Return
30.2%
30.2%
Buy Reco %
81.25
81.25
P/E Ratio
21.24
21.24
1Y Return
48.38%
48.38%
Buy Reco %
67.85
67.85
Forecast
Forecast
Price
Revenue
Earnings
Price Forecast
Price Forecast
2026
Current$10.76Baseline
Analyst Target - 1 year
Target$8-25.65%
All values in $
2026
Current$10.76Baseline
Analyst Target - 1 year
Target$8-25.65%
All values in $
Revenue Forecast
Revenue Forecast
Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.
The next fiscal year's mean estimate implies -50.01% growth, versus a trailing 3-year CAGR of -29.11%.
2025
Current$170.15Baseline
Forecast for Dec 2026
High$90-47.11%
Average$85.06-50.01%
Low$82.2-51.69%
All values in $ Million
2025
Current$170.15Baseline
Forecast for Dec 2026
High$90-47.11%
Average$85.06-50.01%
Low$82.2-51.69%
All values in $ Million
Earnings Per Share Forecast
Earnings Per Share Forecast
2025
Current$-5.65Baseline
Forecast for Dec 2026
High$-2.66+52.92%
Average$-2.93+48.14%
Low$-3.2+43.36%
All values in $
2025
Current$-5.65Baseline
Forecast for Dec 2026
High$-2.66+52.92%
Average$-2.93+48.14%
Low$-3.2+43.36%
All values in $
Financials
Financials
Income
Balance Sheet
Cash Flow
Quarterly Normal View
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
| Financial Year | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 37.94 | 56.20 | 89.04 | 43.84 | 48.31 | 49.60 | 38.83 | 33.39 | 19.47 | 20.15 |
Gross Profit | 28.74 | 42.48 | 79.05 | 34.22 | 36.27 | 34.78 | 26.03 | 41.54 | 3.57 | 18.43 |
| Net Income | -165.91 | -217.18 | -56.40 | -107.53 | -90.95 | -60.3 | -80.75 | -80.75 | -82.58 | -46.71 |
| Net Profit Margin | -437.25% | -386.40% | -63.34% | -245.24% | -188.24% | -121.56% | -207.93% | -241.79% | -424.08% | -231.74% |
Peers
Peers & Comparison
Peers & Comparison
Comparing 2 stocks from
HealthcareBiotechnology
HealthcareBiotechnology
Valuation
Returns
Forecast
Compare valuation on Screener| Stock | PE TTMPE TTM | PBPB | PEG RatioPEG Ratio |
|---|---|---|---|
| Ginkgo Bioworks Holdings | - | 1.79 | - |
| AbbVie Inc | 50.67 | 50.45 | 0.60 |
| Amgen Inc | 28.90 | 21.55 | 2.77 |
Price Comparison
Price Comparison
Compare DNA with any stock or ETFCompare DNA with any stock or ETF
Comparing from
DNA
ABBV
AMGN
The 12-month consensus target implies -25.65% growth, versus a trailing 3-year CAGR of -43.86%.